Sunesis to Present at ROTH 23rd Annual OC Growth Stock Conference
2011年3月9日 - 9:29PM
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSSD) a biopharmaceutical
company focused on the development and commercialization of new
oncology therapeutics for the treatment of solid and hematologic
cancers, today announced that Senior Vice President of Corporate
Development & Finance and Chief Financial Officer, Eric
Bjerkholt, will be presenting at the ROTH 23rd Annual OC Growth
Stock Conference on Monday, March 14th at 3:30 PM Pacific Time
(6:30 PM Eastern Time), at The Ritz Carlton in Laguna Niguel,
California. This presentation will not be webcast.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the
development and commercialization of new oncology therapeutics for
the treatment of solid and hematologic cancers. Sunesis has built a
highly experienced cancer drug development organization committed
to advancing its lead product candidate, vosaroxin, in multiple
indications to improve the lives of people with cancer. For
additional information on Sunesis, please visit
http://www.sunesis.com.
SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals,
Inc.
The Sunesis Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8773
CONTACT: Andrea Rabney
Argot Partners
212-600-1902
Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717
Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
過去 株価チャート
から 5 2024 まで 6 2024
Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Sunesis Pharmaceuticals, Inc. (MM) (ナスダック市場): 0 recent articles
その他のSunesis Pharmaceuticals, Inc.ニュース記事